Osterweis Capital Management Inc. Buys Shares of 111,458 Twist Bioscience Corporation $TWST

Key Points

• Osterweis Capital Management initiated a position in Twist Bioscience, buying 111,458 shares valued at approximately $11.5 million, or 0.18% of the company. Several other institutional investors also increased or initiated holdings.
• Twist Bioscience reported quarterly revenue of $118.4 million, up 23.2% year over year and above estimates, but its loss of $0.56 per share missed expectations. Analysts project a full-year loss of $2.12 per share.
• The stock opened at $140.80, near its 52-week high of $145.93, despite continued insider selling. Analysts maintain a “Moderate Buy” consensus, with an average price target of $98.30.

Osterweis Capital Management Inc. purchased a new stake in Twist Bioscience Corporation (NASDAQ:TWST - Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 111,458 shares of the company's stock, valued at approximately $11,467,000. Osterweis Capital Management Inc. owned 0.18% of Twist Bioscience as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. Quarry LP bought a new stake in Twist Bioscience in the third quarter valued at about $28,000. Western Wealth Management LLC acquired a new position in Twist Bioscience in the first quarter valued at about $31,000. Strs Ohio bought a new position in Twist Bioscience during the first quarter worth about $33,000. Strategic Advocates LLC boosted its holdings in Twist Bioscience by 562.7% during the fourth quarter. Strategic Advocates LLC now owns 1,067 shares of the company's stock worth $34,000 after buying an additional 906 shares during the last quarter. Finally, SBI Securities Co. Ltd. grew its position in shares of Twist Bioscience by 68.9% during the 4th quarter. SBI Securities Co. Ltd. now owns 1,400 shares of the company's stock worth $44,000 after buying an additional 571 shares during the period.

Insider Activity at Twist Bioscience

In related news, SVP Paula Green sold 291 shares of the business's stock in a transaction on Monday, June 22nd. The shares were sold at an average price of $87.32, for a total value of $25,410.12. Following the sale, the senior vice president directly owned 120,414 shares of the company's stock, valued at approximately $10,514,550.48. The trade was a 0.24% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Emily M. Leproust sold 113,318 shares of the company's stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $125.16, for a total value of $14,182,880.88. Following the transaction, the chief executive officer directly owned 818,938 shares of the company's stock, valued at $102,498,280.08. This represents a 12.16% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 151,529 shares of company stock valued at $17,708,772. Insiders own 3.08% of the company's stock.

Twist Bioscience Price Performance

NASDAQ TWST opened at $140.80 on Tuesday. The business has a 50 day simple moving average of $101.89 and a 200 day simple moving average of $71.16. Twist Bioscience Corporation has a 52-week low of $23.30 and a 52-week high of $145.93. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.38 and a current ratio of 2.67. The stock has a market cap of $8.83 billion, a price-to-earnings ratio of -63.42 and a beta of 2.14.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last announced its quarterly earnings results on Monday, August 3rd. The company reported ($0.56) earnings per share for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.05). The company had revenue of $118.38 million during the quarter, compared to the consensus estimate of $114.55 million. Twist Bioscience had a negative net margin of 31.66% and a negative return on equity of 28.64%. The business's quarterly revenue was up 23.2% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.33 EPS. Analysts anticipate that Twist Bioscience Corporation will post -2.12 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

TWST has been the subject of a number of recent analyst reports. Barclays upped their price target on Twist Bioscience from $65.00 to $95.00 and gave the company an "overweight" rating in a research note on Wednesday, June 24th. UBS Group set a $89.00 target price on shares of Twist Bioscience in a research note on Monday, June 15th. TD Cowen reissued a "buy" rating on shares of Twist Bioscience in a report on Monday, August 3rd. Leerink Partners set a $110.00 price objective on shares of Twist Bioscience in a research report on Thursday, July 16th. Finally, Evercore cut shares of Twist Bioscience from an "outperform" rating to an "in-line" rating and set a $102.00 price objective for the company. in a research report on Monday, July 6th. Eight investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $98.30.

Twist Bioscience Company Profile

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist's offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source